Serotonin syndrome risk with antiobesity drug

Canadian Journal of Clinical Pharmacology

Volumn 7, Issue 4, 2000, Pages 216-

  Trakas, K ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ANTIDEPRESSANT AGENT; ANTIOBESITY AGENT; DEXFENFLURAMINE; SEROTONIN; SEROTONIN 1A RECEPTOR; SIBUTRAMINE; SUMATRIPTAN; SUMATRIPTAN SUCCINATE;

AGITATION; COMA; CONFUSION; DIAPHORESIS; DIARRHEA; FEVER; HUMAN; HYPERICUM PERFORATUM; HYPERREFLEXIA; HYPERTENSION; HYPOMANIA; HYPOTENSION; LETTER; MOTOR DYSFUNCTION; MYOCLONUS; OBESITY; RESTLESSNESS; SEIZURE; SEROTONIN SYNDROME; SHIVERING; TACHYCARDIA; TREMOR;

EID: 0034488072     PISSN: 1198581X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (6)

1. The serotonin syndrome
2. 1A receptor in 5-HT syndrome induced in mice by tryptamine
3. Obesity in Canada: A descriptive analysis
4. Introductory Version
5. Utilization of health care resources by obese Canadians
6. The serotonin syndrome and its treatment